Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00723892
First received: July 25, 2008
Last updated: June 23, 2014
Last verified: June 2014
Results First Received: August 25, 2010  
Study Type: Observational
Study Design: Observational Model: Cohort;   Time Perspective: Prospective
Conditions: Hepatitis C, Chronic
Hepacivirus
Interventions: Biological: Peginterferon alfa-2b (PegIntron)
Drug: Rebetol (Ribavirin)
Behavioral: Psychotherapy support program

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
614 participants were recruited in this study.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Only 568 participants were assigned to treatment as they were foreseen to complete treatment, were consulted, and met inclusion criteria.

Reporting Groups
  Description
PegIntron/Rebetol and Psychotherapy Support Program Participants receiving a psychotherapy support program during PegIntron/Rebetol therapy for hepatitis C.
PegIntron/Rebetol Alone (no Psychotherapy) Participants receiving no psychotherapy support program during PegIntron/Rebetol therapy for hepatitis C.

Participant Flow:   Overall Study
    PegIntron/Rebetol and Psychotherapy Support Program     PegIntron/Rebetol Alone (no Psychotherapy)  
STARTED     313     255  
COMPLETED     206     168  
NOT COMPLETED     107     87  
Participant not tracked                 33                 35  
Virological criterion                 24                 9  
Withdrawal by Subject                 6                 9  
End planned                 11                 7  
Bad tolerance                 5                 5  
Multiple reasons                 17                 12  
Not specified                 6                 3  
Study end                 1                 3  
Weight loss                 1                 3  
Alcohol abuse                 0                 1  
Intercurrent infection                 2                 0  
Drug addiction                 1                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
PegIntron/Rebetol and Psychotherapy Support Program Participants receiving a psychotherapy support program during PegIntron/Rebetol therapy for hepatitis C.
PegIntron/Rebetol Alone (no Psychotherapy) Participants receiving no psychotherapy support program during PegIntron/Rebetol therapy for hepatitis C.
Total Total of all reporting groups

Baseline Measures
    PegIntron/Rebetol and Psychotherapy Support Program     PegIntron/Rebetol Alone (no Psychotherapy)     Total  
Number of Participants  
[units: participants]
  313     255     568  
Age [1]
[units: years]
Mean ± Standard Deviation
  45.5  ± 10.7     48.5  ± 11.8     46.8  ± 11.3  
Gender, Customized [1]
[units: participants]
     
Female     117     80     197  
Male     195     175     370  
Unavailable (missing data)     1     0     1  
Region of Enrollment [1]
[units: participants]
     
France     313     255     568  
[1] Participants foreseen to complete treatment, consulted and assigned to treatment were analyzed.



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants Who Complete Treatment With PegIntron/Rebetol Therapy for Hepatitis C When Administered With a Patient Psychotherapy Support Program as Compared to a Group Without a Psychotherapy Support Program.   [ Time Frame: 12 months after onset of treatment ]

2.  Secondary:   the Average Length of Treatment for Participants on Treatment for Hepatitis C With PegIntron Pen/Rebetol   [ Time Frame: 12 months after onset of treatment ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Vice President, Late Stage Development Group Leader
Organization: Merck Sharp & Dohme Corp.
phone: 1-800--672-6372
e-mail: ClinicalTrialsDisclosure@merck.com


No publications provided


Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00723892     History of Changes
Other Study ID Numbers: P04252, MK-4031-245
Study First Received: July 25, 2008
Results First Received: August 25, 2010
Last Updated: June 23, 2014
Health Authority: France: Ministry of Health